Poland· PL-100506136
Yndivan
A valsartan und diuretika product containing valsartanum + indapamidum, registered in Poland by Gedeon Richter Polska Sp. z o.o.. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Valsartan und diuretika is registered in 13 of 19 countries.
Countries holding a registration under ATC C09DA03 (valsartan und diuretika), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Valsartan und diuretika · ATC C09DA03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Valsartanum + Indapamidum
- Manufacturer
- Gedeon Richter Polska Sp. z o.o.
- Country
- Poland (PL)
- ATC code
- C09DA03
- ATC class
- Valsartan und Diuretika
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin05907594033887
- gtin05907594033894
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
80 interactions on record for valsartan und diuretika.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Valsartan und diuretika · interactions on record
80 records
80 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame medicine, other countries
Valsartan und diuretika in 4 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVABINXOKrka, d.d., Novo mesto, Novo mesto
- GermanyValsainda ApontisKrka, D.D., Novo Mesto
- SpainVALOMINDO 160 MG/1,5 MG COMPRIMIDOS DE LIBERACION MODIFICADAKrka D.D. Novo Mesto
- FinlandValomindoKRKA d.d. Novo mesto
Authorised across Europe · EMA
The same active substance is authorised in 17 EEA countries. Names it is sold under:
- Austria · Valsartan/Indapamid Tad
- Bulgaria · Валоминдо, Валсартан/Индапамид Билев
- Cyprus · Valomindo
- Czechia · Vabinxo, Valsartan/Indapamid Krka
- Germany · Valsainda Apontis, Vamipino
- Estonia · Vabinxo, Yndivan
- Spain · Valomindo
- Finland · Valomindo
- Greece · Valomindo
- Croatia · Valomindo
- Hungary · Norsiten, Vabincor
- Lithuania · Vabinxo
- Latvia · Vabinxo, Yndivan
- Portugal · Valomindo
- Romania · Valomindo, Yndivan
- Slovenia · Valomindo
- Slovakia · Vabinxo, Yndivan
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c86b6ac4-b819-4bd2-ad6b-d21395ebbe48 GET /v1/drugs/c86b6ac4-b819-4bd2-ad6b-d21395ebbe48?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki o zmodyfikowanym uwalnianiu",
"source": "urpl",
"strength": "160 mg + 1,5 mg",
"packaging": "05907594033887 ¦ Rp ¦ 166464\n30 tabl.\n05907594033894 ¦ Rp ¦ 166465\n90 tabl.",
"substance": "Valsartanum 160 mg + Indapamidum 1.5 mg",
"common_name": "Valsartanum + Indapamidum",
"pl_product_id": "100506136",
"pozwolenie_nr": "29601",
"auth_procedure": "DCP",
"authorisation_validity": "2031-03-20"
}See everything about valsartan und diuretika.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.